This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Cyclacel Pharmaceuticals Toekomstige groei
Future criteriumcontroles 5/6
Cyclacel Pharmaceuticals is forecast to grow earnings and revenue by 52.2% and 57.5% per annum respectively while EPS is expected to grow by 46.4% per annum.
Belangrijke informatie
52.2%
Groei van de winst
46.4%
Groei van de winst per aandeel
| Biotechs winstgroei | 35.0% |
| Inkomstengroei | 57.5% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 17 Jan 2024 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 56 | 25 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -27 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -24 | N/A | N/A | 2 |
| 12/31/2023 | 0 | -23 | N/A | N/A | 3 |
| 9/30/2023 | 0 | -25 | -17 | -17 | N/A |
| 6/30/2023 | 0 | -24 | -20 | -20 | N/A |
| 3/31/2023 | N/A | -23 | -21 | -21 | N/A |
| 12/31/2022 | N/A | -21 | -21 | -21 | N/A |
| 9/30/2022 | N/A | -19 | -20 | -20 | N/A |
| 6/30/2022 | N/A | -19 | -19 | -19 | N/A |
| 3/31/2022 | N/A | -20 | -22 | -22 | N/A |
| 12/31/2021 | N/A | -19 | -19 | -19 | N/A |
| 9/30/2021 | N/A | -20 | -15 | -15 | N/A |
| 6/30/2021 | N/A | -18 | -11 | -11 | N/A |
| 3/31/2021 | N/A | -15 | -9 | -9 | N/A |
| 12/31/2020 | N/A | -12 | -8 | -8 | N/A |
| 9/30/2020 | N/A | -8 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -8 | -8 | -8 | N/A |
| 3/31/2020 | N/A | -7 | -9 | -9 | N/A |
| 12/31/2019 | N/A | -8 | -9 | -9 | N/A |
| 9/30/2019 | 0 | -8 | -10 | -10 | N/A |
| 6/30/2019 | 0 | -8 | -9 | -9 | N/A |
| 3/31/2019 | 0 | -8 | -8 | -8 | N/A |
| 12/31/2018 | 0 | -7 | -7 | -7 | N/A |
| 9/30/2018 | N/A | -8 | -7 | -7 | N/A |
| 6/30/2018 | N/A | -14 | -7 | -7 | N/A |
| 3/31/2018 | N/A | -15 | -6 | -6 | N/A |
| 12/31/2017 | N/A | -15 | -7 | -7 | N/A |
| 9/30/2017 | 0 | -16 | -8 | -8 | N/A |
| 6/30/2017 | 0 | -10 | N/A | -10 | N/A |
| 3/31/2017 | 1 | -11 | N/A | -11 | N/A |
| 12/31/2016 | 1 | -12 | N/A | -10 | N/A |
| 9/30/2016 | 1 | -13 | N/A | -10 | N/A |
| 6/30/2016 | 1 | -12 | N/A | -11 | N/A |
| 3/31/2016 | 2 | -13 | N/A | -13 | N/A |
| 12/31/2015 | 2 | -15 | N/A | -14 | N/A |
| 9/30/2015 | 2 | -16 | N/A | -15 | N/A |
| 6/30/2015 | 2 | -18 | N/A | -18 | N/A |
| 3/31/2015 | 2 | -20 | N/A | -19 | N/A |
| 12/31/2014 | 2 | -20 | N/A | -19 | N/A |
| 9/30/2014 | 2 | -18 | N/A | -20 | N/A |
| 6/30/2014 | 1 | -19 | N/A | -16 | N/A |
| 3/31/2014 | 1 | -13 | N/A | -18 | N/A |
| 12/31/2013 | 1 | -20 | N/A | -18 | N/A |
| 9/30/2013 | 1 | -21 | N/A | -15 | N/A |
| 6/30/2013 | 1 | -18 | N/A | -15 | N/A |
| 3/31/2013 | 0 | -23 | N/A | -14 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: UXI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Winst versus markt: UXI is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: UXI is expected to become profitable in the next 3 years.
Omzet versus markt: UXI's revenue (57.5% per year) is forecast to grow faster than the German market (5.4% per year).
Hoge groei-inkomsten: UXI's revenue (57.5% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if UXI's Return on Equity is forecast to be high in 3 years time